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EDITORIAL

PGX: Pharmacogenomics During Generation X

Y

ears ago, a pharmacologist informed a group of physicians treating high blood pressure that a great deal
of time was spent treating patients with hydralazine who
would not respond to it. He stated that a hydralazine test
dose of 10 mg would resolve the issue for many. No
blood pressure–lowering response from that dose would
predict an equally impotent result from the ensuing and
multiple, relatively slow dose escalations—the wont of
most treating individuals. Consciously or not, the pharmacologist was stating that the relationship between a
drug and its efﬁcacy, which represented the culmination
of multiple metabolic and biologic factors, lay in the
genes.
Now, we appreciate that the differential effect of hydralazine on patients is genotypically attributable to human,
hepatic arylamine N-acetyltransferase 2 activity.1
Arylamine N-acetyltransferase 2 single nucleotide polymorphisms (SNPs) determine acetylation status, with
rapid acetylators requiring greater drug exposure for efﬁcacy. Approximately an eighth of individuals possess the
rapid acetylation phenotype, a third the slow phenotype,
and the remainder with an intermediate phenotype.2
In terms of blood pressure efﬁcacy, slow acetylators
demonstrate the greatest blood pressure reductions. In
addition, the frequency of serious adverse events (SAEs)
corresponds with the slow acetylator phenotype.
In this issue of Advances of Chronic Kidney Diseases,
Amy Barton Pai, PharmD, has ﬁelded a talented group of
similar ilk who explicate the relationship between
individual drug responses and genes, using multigene
analysis or whole-genome SNP proﬁling.3 This is the discipline of pharmacogenomics (PGX)—a prerequisite to the
promise of personalized health care.4 PGX has existed for
more than 30 years but been greatly underappreciated by
those who prescribe medications, the majority of whom
preceded Generation X, namely, Baby Boomers born
between 1945 and 1964.5,6 PGX began during the period of
Gen Xers, born between the years 1965 and 1984, and
represents the study of how genes affect an individual’s
response to drugs. PGX requires intricate mapping of
the 4 pharmacokinetic processes of drugs, absorption,
distribution, metabolism, and excretion (ADME) and their
associated pharmacodynamic, molecular drug–receptor
interactions to the multiple variants of relevant genes and

target genes of drugs. The mathematical possibilities
and thus variability are staggering, especially if one
acknowledges that there are 105 variant alleles of the
gene CYP2D6; CYP2D6 represents one class of drugmetabolizing enzymes.3 This vast amount of information is
collated and curated by Montreal-based PharmaADME.
org,7 a conjoint enterprise of academia and genomic and
pharmaceutical technology industries that houses the Core
ADME genes and Core Markers (SNPs) with the intent of
improving the drug development cycle in terms of safety
and efﬁcacy for subpopulations. The result of this consortium
is 2 lists: key phase 1 and 2 drug-metabolizing enzymes and
transporter genes that inﬂuence drug ADME and clinically
relevant SNP and copy number variants. This information
is subsequently used to design microarrays that can perform
rapid throughput screening for allelic variants.
In terms of drug therapy, a “one-size-ﬁts-all” approach
is commonly practiced but fails miserably, particularly
for those persons who develop serious adverse reactions
to commonplace medications. The leading cause of death
of inpatients is adverse drug reactions.8 These untoward
drug-related reactions add hundreds of billions to health
care costs in the United States, increasing length-of-stay
in hospitalized patients and hospitalizing those in the
ambulatory care setting and in long-term care facilities,
especially older adults.9-12
Angioedema from angiotensin-converting–enzyme inhibitor administration with a mortality rate once at
11%,13 allopurinol-induced drug rash with eosinophilia
and systemic symptoms (DRESS) with a 20% mortality
rate,14 and aspirin hypersensitivity (not salicylism due to
chronic aspirin overuse)15 all represent manifestations of
minor changes in the genetic code with major and potentially devastating outcomes.
The SAEs cited are not so-called idiosyncratic reactions
or immunologic reactions, that is, allergies, but probabilistic phenomena hardwired into one’s genes. A common
feature of these pharmacogenomically driven drug side
effects is that they all involve alterations of drug
Ó 2016 by the National Kidney Foundation, Inc. All rights reserved.
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metabolism whereby the accumulation of toxic byproducts or end products of metabolism proceeds leading
to SAEs. In angiotensin-converting-enzyme inhibitor
(ACEI)-induced angioedema, inhibition of kininase II
otherwise known as ACE leads to enhanced plasma
bradykinin levels with tissue accumulation and mediates
angioedema. This enhancement is further augmented
by “naturally” low aminopeptidase P and dipeptidyl
peptidase IV levels, 2 enzymes known to catabolize
ACEI,16,17 in genetically predisposed individuals. For
those at risk for allopurinol hypersensitivity, especially
people of Korean, Thai, or Han Chinese descent who
harbor at least one HLA-B*58:01 allele, allopurinol is
contraindicated.18 For those suffering gout in these ethnic
groups, the hepatic metabolite oxypurinol (available on a
compassionate basis), which is much more effective than
its parent compound, or febuxostat are the only other
available xanthine oxidase inhibitors available in the
United States. Tellingly, the Food and Drug Administration label for allopurinol mentions nothing about HLA-B
genotype carriage despite its profound, clinical signiﬁcance. However, Clinical Pharmacogenomics Implementation Consortium recently contraindicated allopurinol
for HLA-B*58:01 carriers to avoid severe cutaneous
adverse reactions in predisposed individuals.19
PGX may hold promise for CKD patients who require
antiplatelet therapy with clopidogrel or anticoagulation
with warfarin. CKD patients with coronary artery disease
may require clopidogrel to maintain stent patency,
stroke prevention, or for prophylaxis of vascular access
thrombosis. This agent’s antiplatelet activity hinges on
enzymatic activation by functional CYP2C19. Some populations such as the Amish encounter less clopidogrel exposure due to a loss-of-function of 1 or more CYP2C19 alleles
(CYP2C19*2, CYP2C19*3, and CYP2C19*17) with consequently decreased drug efﬁcacy.20 Poor metabolizer status
is attributable to CYP2C19 status and was associated
with greater cardiovascular event rates and death in
several studies.21,22 However, in a large (N .5000),
retrospective analysis, treatment outcomes were not
correlated with metabolizer status, except for a positive
beneﬁt conferred by the ultrarapid metabolizer enzyme
variant CYP2C19*17.23
CKD patients, at least for the near-term, will continue to
be treated with warfarin for stroke prevention, pulmonary
embolism prophylaxis, and the inhibition of cardiac valve
clotting. Warfarin is comprised of equal amounts of S and
R enantiomers. S-warfarin is more potent than R-warfarin
and metabolized principally by CYP2C9. The R-isomer is
metabolized by enzymes encoded by the genes for
CYP1A2, CYP2C19, and CYP3A4. Extensive warfarin
metabolizers have 2 wild-type copies of the polymorphic
CYP2C9 gene CYP2C9*1.24 Individuals homozygous
or heterozygous for the allelic variants CYP2C9*2/3
metabolize S-warfarin 50% to 90% slower, and thus are
more greatly anticoagulated at equivalent doses than
those with the wild-type phenotype.25, 26 The recent
development of validated tests that determine which
individuals respond to warfarin better is potentially
lifesaving, given that excessive bleeding from this

coumarin is one of the nation’s most frequent causes for
inadvertent hospital admission.27 Multiplex testing for
prediction of warfarin action may be required because
the target of warfarin, vitamin K 2,3-epoxide reductase
(VKOR), is also polymorphic.28 VKOR inhibition by
warfarin depresses vitamin K–dependent clotting factor
synthesis, but the degree of inhibition at a speciﬁed
warfarin dose may vary by 25% to 50% contingent
on the VKORC1 subunit SNP variants (VKORC1). Enthusiasm for warfarin pharmacogenomic kit testing is mild at
best, and there is no endorsement by any cardiovascularor kidney-related guideline group for physicians to
routinely conduct pharmacogenomic testing.
The advent of the novel oral anticoagulants such as
dabigatran, apixaban, and rivaroxaban may obviate the
requirement for warfarin in some clinical scenarios. To
date, the largest trial of warfarin pharmacogenomic
testing of CYP29 and VKORC1 was not superior to standard practice of warfarin dosing in maintaining participants in the therapeutic range.29 However, this trial
revealed that genotype-guided testing beneﬁted 2 subgroups: wild-type subjects with greater-than-average
dose requirements and those with multiple variant alleles
who required less-than-average doses. In these 2 subgroups, pharmacogenetic guidance increased withinrange international normalized ratios by nearly 10%
(P ¼ 0.03).
A word of caution though. At this time, we must not
base drug therapy on presumption but on documented
drug responses. The African-American Heart Failure Trial
(A-HeFT)30-32 was predicated on a retrospective, post hoc
analysis of the Veterans Administration Heart Failure
Trial33 that showed more beneﬁt in African Americans
with the drug combination of isosorbide dinitrate/hydralazine. Fixed-dose combinations were tested against placebo in a racial group predicted to be responsive and
were superior. However, this trial did not prove that heart
failure improvement by isosorbide dinitrate/hydralazine
was unique to African Americans, only that the time spent
titrating 2 different drugs was reduced. In essence, one
should not prescribe the heart failure drug armamentarium based solely on race. This is not true for just isosorbide dinitrate/hydralazine but all drugs.
One cannot extrapolate the results of a single, race-based
trial in African-Americans to all racial groups, despite that
BiDil(R) is commercially marketed on a race-speciﬁc basis.
On the other hand, one should not totally exclude future
“race-conscious” therapy. PGX is not based on this principle and represents a part of the solution of successful drug
therapy for a given patient. PGX is not the end all and be
all of drug therapy today but holds great promise as a
player in the future of personalized medicine. Nongenetic,
epigenetic inﬂuences, circadian rhythms, and environmental factors will continually impinge on this burgeoning ﬁeld. Biorepository information and SNP databases
will also require a grand merger to optimally develop
algorithms that align functional gene variants and their
associated characteristics to theranostics. Most importantly, clinical effective research in pharmacogenomics
must be carefully designed.
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Such trials already exist. For example, in 2015, the University of Hong Kong began a 24-month enrollment of
their lupus study, Mycophenolic Acid (MPA) Pharmacokinetics and Pharmacogenomics in Lupus Nephritis,34
which hopefully will elucidate whether the measurement
of MPA levels (area under curve, 0–12 hours) in a vulnerable lupus-prone population correlate with clinical parameters and end points, whereas pharmacogenomic
studies will determine whether MPA exposure and clinical outcomes correlate with gene variants.35 This study
will ultimately determine the relevance of a prior study
of Hongkongese in which MPA inhibited expression of
the B-cell activating CD40-ligand residing on CD41
T-cells. The mechanism of disease downregulation
occurred via epigenetic upregulation of histone acetylation that modulated the promoter activity of the applicable inﬂammatory CD41 cells.34 The conduct of such
studies presages the advancement of today’s version of
pharmacogenomics to the next level, just as today’s Gen
Xers are succeeded by the Millennials.
“If it were not for the great variability among individuals, medicine might as well be a science and
not an art.”
—Sir William Osler
Jerry Yee, MD
Department of Internal Medicine
Henry Ford Hospital
Detroit, MI
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